论文部分内容阅读
1 文献来源 Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. [J]. J Clin Oncol, 2008,12(26):4934-4939. 2 证据水平 1b。 3 背景临床试验表明,强化治疗对于≥60岁老年急性髓性白血病(acute myeloid leukemia,AML)患者,疗效远不如年轻患者,完全缓解(complete remission,CR)率低,3年生存率仅10%～15%。因此,不但需要摸索新方法去提高老年患者诱导缓解率,在患者取得缓解后,更需要设法延长其无病生存
1 Literature Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. [J]. J Clin Oncol, 2008, 12 ( 26): 4934-4939. 2 Level of Evidence 1b. 3 Background Clinical trials show that intensive treatment is far less effective than younger patients in ≥60 years of age in patients with acute myeloid leukemia (AML), and the rate of complete remission (CR) is low and the 3-year survival rate is only 10% ~ 15%. Therefore, not only need to explore new ways to improve the induction of remission rate in the elderly patients, the patient remission, but also need to try to prolong their disease-free survival